Why EyePoint, Inc.’s (EYPT) Stock Is Down 6.38%
As of Friday, July 31, EyePoint, Inc.’s EYPT share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why EyePoint, Inc.’s (EYPT) Stock Is Down 5.15%
As of Thursday, July 16, EyePoint, Inc.’s EYPT share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Jenna Brashear
Why EyePoint, Inc.’s (EYPT) Stock Is Down 5.22%
As of Friday, July 10, EyePoint, Inc.’s EYPT share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Michael Rose
Why EyePoint, Inc.’s (EYPT) Stock Is Up 6.35%
As of Thursday, July 09, EyePoint, Inc.’s EYPT share price has surged by 6.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Why EyePoint, Inc.’s (EYPT) Stock Is Up 5.15%
As of Thursday, July 02, EyePoint, Inc.’s EYPT share price has surged by 5.15%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | EYPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,027.1 | $579.1 | 45% |
|
| Shares Out (Mil) | 86.0 | 43.0 | 59% |
|
| Institutional Ownership | 98.9% | 84.3% | 83% |
|
| Float (Mil) | 62.2 | 46.8 | 52% |
|
| Beta | 1.77 | 0.62 | 88% |
|
| Avg Daily Volume (000s) | 1,492 | 285 | 77% |
|
| Price Change (52-week) |
24.5% | 63.8% | 65% |
|
| Growth | EYPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (1.8%) | 6.7% | 13% |
|
| Net Income (5yr) | (38.6%) | (1.4%) | 10% |
|
| EPS (5yr) | 2.2% | 14.9% | 34 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (55.8%) | (14.9%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | na | 12 | |
| Current EPS | ($0.957) | na | ($3.555) | |
| Month Ago EPS | ($0.948) | na | ($3.512) | |
| # Rev Up | 1 | na | 0 | |
| # Rev Down | 0 | na | 1 | |
| Three Months Ago EPS | ($0.833) | na | ($3.240) | |
| Year/Year Chg | (2.9%) | na | (3.9%) | |
| Financials | EYPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $272 | 8% |
|
| Net Income (TTM) (Mil) | ($272) | ($11) | 5% |
|
| EPS (TTM) | ($3.513) | ($0.500) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($268) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $4 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $7 | 33% |
|
| Enterprise Value (Q1) (Mil) | $945 | $522 | 41% |
|
| Valuation | EYPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.44 | 2.73 | 76% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | EYPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (83.5%) | (24.6%) | 7% |
|
| ROE | (102.7%) | (19.7%) | 9% |
|
| Liabilities to Assets | 20.0% | 35.5% | 13% |
|
| F-Score | 2 | 3 | 7% |
|
EyePoint, Inc. did not pass any screens on 7/31/2026.
